Recent advances in Brucella abortus vaccines

Dorneles, Elaine Maria Seles; Sriranganathan, Nammalwar; Lage, Andrey Pereira

doi:10.1186/s13567-015-0199-7

Cited by 149 publications

(133 citation statements)

References 83 publications

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…Massive vaccination against brucellosis in cattle have been performed employing few vaccine strains, S19, RB51, 45/20 and SR82, although many B. abortus vaccine candidates have been developed over the last years, such as DNA, subunit, recombinant B. abortus and recombinant vector vaccines [8]. The 45/20 was a bacterin used in some European countries, but the variability in reported protection, along with unpredictable serological effects and the occurrence of reactions at the site of vaccine injection in some animals led to the interruption of the use of this vaccine [16].…”

Section: B Abortus Vaccines and Vaccinationmentioning

confidence: 99%

“…However, many studies are still needed to achieve the ideal vaccine against brucellosis. The majority of these genetically engineered vaccines was developed and tested using mouse models and they have not been tested or were not protective in cattle [8]. Among the live modified B. abortus vaccines, S19 and RB51, are the most widely used strains around the world.…”

Section: B Abortus Vaccines and Vaccinationmentioning

confidence: 99%

“…One of the most effective measures to reduce the prevalence of bovine brucellosis that has been successfully used in many control programs is the vaccination [7,8]. Strains19 and RB51 are the two B. abortus vaccine strains more largely used in the control of brucellosis in cattle worldwide, being effective in the prevention of abortion and infection, besides offering long lasting protection [9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Brucella Abortus Vaccines: Use in Control Programs and Immune Response

Lage¹

2017

J Bacteriol Mycol

View full text Add to dashboard Cite

Brucella spp. is a highly infectious pathogen that affects numerous livestock and wild animal species besides humans, and that although eradicated in some countries, remains one of the most economically important zoonosis worldwide. Strain 19 and RB51 are the two Brucella abortus vaccine strains more largely used in the control of brucellosis in cattle worldwide, being effective in the prevention of abortion and infection, besides offering long lasting protection. Here, we reviewed the main aspects of the B. abortus vaccines and their use in brucellosis control and eradication programs over the years and the current understanding in the immune response triggered by these two B. abortus vaccines, especially in cattle.

show abstract

Section: B Abortus Vaccines and Vaccinationmentioning

confidence: 99%

Section: B Abortus Vaccines and Vaccinationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Brucella Abortus Vaccines: Use in Control Programs and Immune Response

Lage¹

2017

J Bacteriol Mycol

View full text Add to dashboard Cite

show abstract

“…Parameter 3 -Field protection as reduced morbidity (as reduced susceptibility to infection and/or to disease) B. abortus S19 and B. melitensis Rev.1 remain the most effective vaccines, and when combined with test and slaughter have been instrumental in almost all successful cases of eradication. A single dose of these vaccines confers from 50% to 100% protection against challenges infecting 80-100% of unvaccinated controls (Nicoletti, 1990;Jacques et al, 2007;Barrio et al, 2009;Dorneles et al, 2015). However, quality of product is essential and thus there are internationally accepted quality control protocols for both vaccines (Grill o et al, 2000;OIE, 2016).…”

Section: Effectivenessmentioning

confidence: 99%

Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): infection with Brucella abortus, B. melitensis and B. suis

More¹,

Bøtner²,

Butterworth³

et al. 2017

EFS2

View full text Add to dashboard Cite

The infection with Brucella abortus, Brucella melitensis and Brucella suis has been assessed according to the criteria of the Animal Health Law (AHL), in particular criteria of Article 7 on disease profile and impacts, Article 5 on the eligibility of the infection with B. abortus, B. melitensis and B. suis to be listed, Article 9 for the categorisation of the infection with B. abortus, B. melitensis and B. suis according to disease prevention and control rules as in Annex IV and Article 8 on the list of animal species related to the infection with B. abortus, B. melitensis and B. suis. The assessment has been performed following a methodology composed of information collection and compilation, expert judgement on each criterion at individual and, if no consensus was reached before, also at collective level. The output is composed of the categorical answer, and for the questions where no consensus was reached, the different supporting views are reported. Details on the methodology used for this assessment are explained in a separate opinion. According to the assessment performed, the infection with B. abortus, B. melitensis and B. suis can be considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL. The disease complies with the criteria as in Sections 2, 3, 4 and 5 of Annex IV of the AHL, for the application of the disease prevention and control rules referred to in points (b), (c), (d) and (e) of Article 9(1). The animal species to be listed for the infection with B. abortus, B. melitensis and B. suis according to Article 8(3) criteria are several mammal species, as indicated in the present opinion.

show abstract

“…Live attenuated B. abortus strain 19 and B. melitensis Rev 1 have served as efficacious vaccine strain for cattle and sheep, respectively. [2,3] However, both vaccines have the disadvantages of inducing O-polysaccharide (OPS)-specific antibody responses that interfere with the serological diagnosis of disease. [4] They may cause abortion in vaccinated animals under some circumstances [5] and of being pathogenic for humans.…”

Section: Introductionmentioning

confidence: 99%

Effect of levamisole administration on immunogenic and protective capacity of Brucella abortus RB51

Mansour¹

2017

Natl J Physiol Pharm Pharmacol

View full text Add to dashboard Cite

Background: Brucella abortus strain RB 51 is a rough strain that was derived after multiple passages of virulent strain 2308. Levamisole, a potent anthelmintic that is widely used in veterinary medicine, is also known as an immune stimulant. Aim and Objectives: Determine the capability of levamisole to enhance the humoral antibody response and cellmediated immunity as well as protective capacity of RB 51 vaccine in mice against challenge with virulent Brucella melitensis strain. Materials and Methods: Six groups of 7-8-week-old female Bulb/C mice were used. Group I was vaccinated I/P with 5 × 108 colony-forming units (CFU) of RB 51 strain. Group II was vaccinated I/P with 5 × 108 CFU of RB 51 strain simultaneously injected (at 0 day) s/cu with 12.5 mg/Kg levamisole. Group III was vaccinated I/P with 5 × 108 CFU of RB 51 strain and injected at 7-day postvaccination with 12.5 mg/Kg levamisole. Group IV was vaccinated I/P with 5 × 108 CFU of RB 51 strain and injected at the day of vaccination (0 day) and 7-day postvaccination with 12.5 mg/Kg levamisole. Group V was injected with levamisole alone. Group VI was kept as control group. 8-week postvaccination; all vaccinated as well as control animals groups received I/P challenge of 2 ml dose of 2 × 104 CFU/ml of virulent strain of B. melitensis biovar 3. Results: (Groups III and IV) At the day of vaccination (0 day) and 7-day postvaccination showed the highest significant serum antibody titer measured by ELISA all over the experimental period as well as increase in delayed type hypersensitivity (DTH) response 48 h after elicitation by intradermal inoculation of B. abortus soluble antigen compared to vaccinated control group (Group I). While RB 51 vaccinated and simultaneously treated with levamisole (Group II) showed mild elevation in antibody titer as well as the lowest significant increase in DTH response compared to vaccinated control group. Bioassay test of challenged mice groups showed significant improvement in the resistance of vaccinated groups treated with levamisole either 7-day postvaccination (Group III) or 0 and 7 days postvaccination (Group IV) which showed 10% bacteriologically positive mice, whereas only 30% of the vaccinated control mice (Group I) and vaccinated simultaneously treated with levamisole (Group II), were bacteriologically positive.

show abstract

Recent advances in Brucella abortus vaccines

Cited by 149 publications

References 83 publications

Brucella Abortus Vaccines: Use in Control Programs and Immune Response

Brucella Abortus Vaccines: Use in Control Programs and Immune Response

Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): infection with Brucella abortus, B. melitensis and B. suis

Effect of levamisole administration on immunogenic and protective capacity of Brucella abortus RB51

Contact Info

Product

Resources

About